Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:VSCO News 30 December 2025 - 12 January 2026

Victoria’s Secret stock today: VSCO presses 52-week highs after a 4% jump

Victoria’s Secret stock today: VSCO presses 52-week highs after a 4% jump

NEW YORK, December 30, 2025, 06:09 ET — Premarket Victoria’s Secret & Co shares closed up 4.16% on Monday at $56.05, after trading as high as $56.44 and pushing toward the top of its $13.76-to-$56.95 52-week range. About 2.32 million shares changed hands, with the stock swinging between $53.05 and $56.44. Investing.com The lingerie retailer’s December run has turned it into a year-end momentum name, with traders leaning on the view that its turnaround is starting to show up in profitability. That matters now because apparel stocks can react sharply to any hint of promotion-heavy selling as the holiday quarter
30 December 2025
·

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop